Survey of Pediatric Dermatologist Views on Treatment for Alopecia Areata
August 2023
in “
JAAD international
”
New to Minoxidil? There is a guide in the encyclopedia. Read the guide → 
Studysummary This study observed that most pediatric dermatologists prefer class 1 and 2 topical corticosteroids as first-line treatments for pediatric alopecia areata, with increasing use of JAK inhibitors as second-line therapy.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document is a survey of pediatric dermatologists' treatment preferences for pediatric alopecia areata (PAA). The survey revealed that for PAA patients under 8 years, the primary treatment was class 1 and 2 topical corticosteroids, with secondary treatments including intralesional triamcinolone, topical immunotherapy, and minoxidil 5% solution for those with less than 25% scalp involvement. For patients 8 years and older, class 1 corticosteroids and intralesional triamcinolone were the first-line treatments, with intralesional triamcinolone and topical minoxidil 5% solution as second-line treatments. The survey also found that despite the lack of FDA-approved therapies for PAA, many pediatric dermatologists are using topical and oral Janus kinase inhibitors (JAKi) in treatment, indicating a need for further studies on the safety and efficacy of JAKi for pediatric AA. The study's limitations include selection bias, sample size, and a skew towards junior respondents.
